A single 12-amino-acid peptide just cut food intake by 50 percent in pigs without causing a single case of nausea.
This is not a GLP-1 analog. It is not a synthetic derivative of semaglutide. The molecule, called BRP, does not touch the gut. It does not slow peristalsis. It does not trigger the vomiting reflex. It goes straight to the hypothalamus—the brain's appetite control center—and turns off hunger. The research, led by Katrin Svensson at Stanford Medicine, landed in Nature on March 5, 2025.
The results are a direct refutation of the assumption that "Ozempic-like" must mean "Ozempic-derived."
2,600 Peptides Screened. One Hit.
Svensson's lab did not set out to build a better GLP-1. They asked a different question: does the body already produce its own appetite-suppressing molecules that we have simply never catalogued?
The team used an AI tool called Peptide Predictor to screen more than 2,600 peptide fragments cleaved from prohormones—biologically inert precursor proteins that the body chops into active signaling molecules. Most of these fragments are biological noise. The AI was hunting for ones with hormone-like activity.
BRP emerged from the noise. A 12-amino-acid fragment of a larger prohormone called proopiomelanocortin—POMC—that no one had characterized as a standalone appetite signal. The body was already making it. The AI simply found it.
Here is what is confirmed. A single injection of BRP reduced food intake by up to 50% within one hour in both mice and minipigs. In a two-week study on obese mice, daily injections produced an average weight loss of about 3 grams, almost entirely fat. Untreated mice gained roughly 3 grams over the same period. Treated animals showed improved glucose and insulin tolerance. Behavioral assessments found no measurable changes in movement, water consumption, anxiety-like behavior, or fecal output.
No nausea. No constipation. No muscle wasting. The appetite suppression was surgically clean.
The Gut Was Never the Target
Ozempic works by activating GLP-1 receptors. Those receptors are everywhere—brain, gut, pancreas, other tissues. That broad action is what produces the drug's effects and its side effects. Delayed gastric emptying causes nausea and constipation. The drug's reach into multiple tissues contributes to muscle loss. Real-world discontinuation rates run north of 40% within a year.
BRP does something fundamentally different. Katrin Svensson explained the distinction directly: "The receptors targeted by semaglutide are found in the brain but also in the gut, pancreas and other tissues. That's why Ozempic has widespread effects including slowing the movement of food through the digestive tract and lowering blood sugar levels. In contrast, BRP appears to act specifically in the hypothalamus, which controls appetite and metabolism."
This is the mechanism that matters. BRP is not a GLP-1 agonist. It is not a GIP agonist. It is a distinct signaling molecule that acts on an as-yet-unidentified receptor in the hypothalamus. The pharmaceutical industry has spent decades and billions of dollars building blunt, multi-tissue tools to control appetite. Stanford just demonstrated that the body already has a dedicated appetite-control circuit—and that it can be activated without collateral damage.
BRP improved glucose and insulin tolerance without altering gut motility. Without changing anxiety behavior. Without touching fecal output. The implication is stark: appetite suppression and metabolic disruption are separable. They always were. The industry was simply aiming at the wrong targets.
The $40 Billion Question
If a native human peptide can match semaglutide's appetite suppression while eliminating the side effects that drive half of patients to quit, the entire next-generation GLP-1 pipeline becomes a stopgap. Not a solution. Oral semaglutide. Retatrutide. Orforglipron. These are optimization programs built on the same broad-receptor pharmacology that causes the nausea problem in the first place. They are better versions of a fundamentally flawed approach.
Svensson has co-founded a company to launch clinical trials of BRP in humans. The peptide has not yet been tested in people. But the preclinical data create a specific, falsifiable prediction. Here is the causal chain.
The mechanism is localized to the hypothalamus, so the nausea and delayed gastric emptying that plague GLP-1 drugs should be absent in humans. If tolerability is clean, the efficacy bar is lower—you don't need to beat semaglutide on weight loss, you just need to be good enough while keeping patients on the drug. Current GLP-1 drugs lose a third to half of patients to side effects within the first year. A drug that doubles tolerability—even with equivalent efficacy—captures the market.
The consequence: within 18 months, expect Novo Nordisk and Eli Lilly to begin redirecting R&D spend away from GLP-1 analog optimization and toward neuropeptide-based programs. The logic is not that BRP is proven. The logic is that the mechanism is proven—single-tissue appetite suppression is possible—and the first mover to commercialize it wins. If BRP can be delivered orally, and at 12 amino acids that is a tractable formulation problem, it bypasses the injection barrier that limits GLP-1 adoption to roughly 5% of eligible patients. The addressable market expands by an order of magnitude.
What would prove this prediction wrong? Toxicity in Phase 1. Poor translatability from pig to human. An efficacy ceiling below what GLP-1 drugs already deliver. Any of those would stall the paradigm shift. But the discovery itself is not in question.
This is not a competitor to Ozempic. It is a refutation of the entire GLP-1 design philosophy. For the 40 to 60% of patients who start a GLP-1 drug and stop within a year, BRP represents a path that does not require gritting through months of nausea. The animal data show no changes in movement, water consumption, or anxiety. The suppression is specific. If you are a prescriber, watch for BRP's Phase 1 data. If you are a patient who tried and failed on Wegovy or Ozempic, this is the molecule designed for your biology. If you are an investor, the GLP-1 optimization era has an expiration date. The neuropeptide engineering era is beginning.
A 12-amino-acid fragment that the human body already produces can cut food intake by half without touching the gut. The AI found the switch. The question now is not whether BRP works. It is whether the industry is brave enough to abandon a $40 billion drug class and follow a 12-amino-acid peptide into the hypothalamus.
